YUPELRI
LAMA NEB
Revefenacin · Viatris Specialty LLC (with Theravance Biopharma)
Active Medication & Mechanism
- Revefenacin LAMA175 mcg per 3 mL unit-dose vial
Long-acting muscarinic antagonist (anticholinergic). Inhibits the M3 receptor on airway smooth muscle, producing sustained bronchodilation with once-daily dosing.
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
175 mcg/3 mL
1 vial (175 mcg) nebulized once daily → 175 mcg
FDA Approved
Maintenance treatment of COPD in adults. Administer via a standard jet nebulizer with a mouthpiece connected to an air compressor (studied with the PARI LC Sprint nebulizer and PARI Trek S compressor).
Not Approved
Yupelri is not indicated for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
175 mcg/3 mL 1 vial (175 mcg) nebulized once daily → 175 mcg
COPD FDA Approved
Maintenance treatment of COPD in adults. Administer via a standard jet nebulizer with a mouthpiece connected to an air compressor (studied with the PARI LC Sprint nebulizer and PARI Trek S compressor).
Asthma Not Approved
Yupelri is not indicated for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute bronchospasm or rescue. Use a SABA.